PulseSight Therapeutics Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Series A
- Investors
-
11
PulseSight Therapeutics General Information
Description
Developer of therapeutic proteins designed to treat severe retinal diseases. The company's proteins treat both short and long-term conditions like chronic non-infectious uveitis, degenerative diseases, retinal vascular diseases and macular edema, as well as enhance compliance, ocular bioavailability and tolerability, enabling physicians and ophthalmologists to improve quality of life and preserve vision for patients.
Contact Information
Website
www.pulsesight.comCorporate Office
- PariSante Campus, 2-10 Rue dOradour-sur-Glane
- 75015 Paris
- France
Corporate Office
- PariSante Campus, 2-10 Rue dOradour-sur-Glane
- 75015 Paris
- France
PulseSight Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A) | 13-Feb-2025 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC | 28-Feb-2024 | Completed | Pre-Clinical Trials | |||
| 6. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 5. Later Stage VC (Series B) | 04-Aug-2021 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 3. Later Stage VC (Series B) | 04-Jul-2019 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC (Series A) | 15-Sep-2016 | $10.1M | $12.9M | Completed | Pre-Clinical Trials | |
| 1. Later Stage VC | 11-Apr-2013 | $2.77M | $2.77M | Completed | Startup |
PulseSight Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Shares B1 | ||||||||
| ABSA B | ||||||||
| B Shares | ||||||||
| B Shares | ||||||||
| ABSA A | 422,297 | $0.011827 | $23.65 | $23.65 | 1x | $23.65 | 15.5% | |
| BSA 12-2011 | 140,010 | $0.011827 | $18.1 | $18.1 | 1x | $18.1 | 5.14% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
PulseSight Therapeutics Comparisons
Industry
Financing
Details
PulseSight Therapeutics Competitors (16)
One of PulseSight Therapeutics’s 16 competitors is SparingVision, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SparingVision | Venture Capital-Backed | Paris, France | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| jCyte | Venture Capital-Backed | Newport Beach, CA | ||||
| EyePoint | Corporation | Watertown, MA | ||||
| Coave Therapeutics | Venture Capital-Backed | Paris, France |
PulseSight Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PulseSight Therapeutics Patents
PulseSight Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4698206-A1 | Decorin-based compositions for repair and regeneration of retinal pigment epithelium | Pending | 21-Apr-2023 | ||
| WO-2024218311-A1 | Decorin-based compositions for repair and regeneration of retinal pigment epithelium | Inactive | 21-Apr-2023 | ||
| FR-3111913-A1 | Construction of dna for the treatment of eye pathologies | Inactive | 30-Jun-2020 | ||
| AU-2021298865-A1 | Dna structure for treating ocular pathologies | Pending | 30-Jun-2020 | ||
| CA-3182197-A1 | Dna structure for treating ocular pathologies | Pending | 30-Jun-2020 | A61K48/005 |
PulseSight Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PulseSight Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ND Capital | Venture Capital | Minority | ||
| SPRIM Global Investments | Holding Company | Minority | ||
| GF Securities | Investment Bank | Minority | ||
| Kinled Holding | Family Office | |||
| Korea Investment Partners | Venture Capital | Minority |
PulseSight Therapeutics FAQs
-
When was PulseSight Therapeutics founded?
PulseSight Therapeutics was founded in 2008.
-
Where is PulseSight Therapeutics headquartered?
PulseSight Therapeutics is headquartered in Paris, France.
-
What is the size of PulseSight Therapeutics?
PulseSight Therapeutics has 13 total employees.
-
What industry is PulseSight Therapeutics in?
PulseSight Therapeutics’s primary industry is Drug Discovery.
-
Is PulseSight Therapeutics a private or public company?
PulseSight Therapeutics is a Private company.
-
What is PulseSight Therapeutics’s current revenue?
The current revenue for PulseSight Therapeutics is .
-
How much funding has PulseSight Therapeutics raised over time?
PulseSight Therapeutics has raised $57M.
-
Who are PulseSight Therapeutics’s investors?
ND Capital, SPRIM Global Investments, GF Securities, Kinled Holding, and Korea Investment Partners are 5 of 11 investors who have invested in PulseSight Therapeutics.
-
Who are PulseSight Therapeutics’s competitors?
SparingVision, ONL Therapeutics, jCyte, EyePoint, and Coave Therapeutics are some of the 16 competitors of PulseSight Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
